HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial

Clinical trial NCT04833023 · UNKNOWN

Trial details

NCT number: NCT04833023
Sponsor: Tan Tock Seng Hospital
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Haloperidol Advanced Cancer Hyperactive Delirium Olanzapine End-stage Organ Disease

Start date: 2022-05-18
Primary completion: 2024-12-01
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.